Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilematovir - Janssen Sciences Ireland UC

Drug Profile

Rilematovir - Janssen Sciences Ireland UC

Alternative Names: JNJ-53718678; JNJ-678; JNJ-8678

Latest Information Update: 23 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Sciences Ireland UC
  • Developer Janssen Research & Development; Janssen Sciences Ireland UC
  • Class Antivirals; Halogenated hydrocarbons; Imidazoles; Indoles; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 23 May 2022 Janssen Sciences Ireland completes pre-approval access programme for Respiratory Syncytial Virus (In Adults, In Children, In the elderly) in Hungary, Italy, Spain, Sweden, and the United Kingdom (PO) in May 2022 (NCT04221412)
  • 28 Apr 2022 Janssen Research and Development terminates a phase IIb PRIMROSE trial in Respiratory syncytial virus infections (In adults, In the elderly) in Argentina, Bulgaria, Canada, Germany, Hungary, Italy, Japan,Poland, South Africa, Spain, Sweden, Thailand, Ukraine and in the US, due strategic decision (NCT04978337).
  • 27 Apr 2022 Janssen Research & Development terminates a phase III clinical trials in Respiratory syncytial virus infections (In children, In infants, In neonates) in Poland, Belgium, Czech Republic, Hungary, Sweden, Germany, Spain (PO) (NCT04583280) (EudraCT2020-002023-11)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top